Biosafety and action in front of COVID-19

What do we know?

Authors

  • Anna Clara Cachoni University of the State of Paraná Author
    • Micael Borges Cadari University of the State of Paraná Author
      • Augusto Alberto Foggiato University of the State of Paraná Author
        • Juliana Zorzi Coléte University of the State of Paraná Author
          • João Lopes Toledo Neto University of the State of Paraná Author
            • Fabrício José Jassi University of São Paulo image/svg+xml Author
              • Douglas Fernandes da Silva Universidade Paulista image/svg+xml Author

                DOI:

                https://doi.org/10.31686/ijier.vol9.iss4.3031

                Keywords:

                Biosafety, SARS-CoV-2, Cross Infection, Health Professionals, COVID-19, Personal Protective Equipment (PPE).

                Abstract

                The COVID-19 disease that affected the entire world in 2020 is caused by a virus (SARS-CoV-2) with a high rate of pathogenicity and transmission that caused several deaths in its trajectory. To combat this disease several personal hygiene measures and the use of personal protective equipment were necessary. In view of this, the study aims to clarify some doubts regarding the vaccine and its effectiveness, individual protection and the performance of health professionals in the face of this situation.

                Author Biographies

                • Anna Clara Cachoni, University of the State of Paraná

                  Graduate student in dentistry

                • Micael Borges Cadari, University of the State of Paraná

                  Graduate student in dentistry

                • Augusto Alberto Foggiato, University of the State of Paraná

                  Dentist, Specialist in Radiology, Orthodontics and Facial Orthopedics

                • Juliana Zorzi Coléte, University of the State of Paraná

                  Dentist, DDS, MSc, PhD, Post-doc on Oral & Maxillofacial Surgery and Implantology

                  Health Sciences Center - Dentistry

                • João Lopes Toledo Neto, University of the State of Paraná

                  Dentist and PhD of oral-biology by the Faculty of Dentistry of Piracicaba Unicamp

                  Health Sciences Center -Dentistry

                • Fabrício José Jassi, University of São Paulo

                  Physiotherapist and PhD rehabilitation and functional performance - School of Physical Education and Sport of Ribeirão Preto

                • Douglas Fernandes da Silva, Universidade Paulista

                  Biologist, biotechnological engineer and PhD in applied microbiology

                References

                ABDULLAHI, I. N.; EMERIBE, A. U.; AJAYI, O. A.; ODERINDE, B. S.; AMADU, D. O.; OSUJI, A. I. Implications of SARS-CoV-2 genetic diversity and mutations on pathogenicity of the COVID-19 and biomedical interventions. Journal of Taibah University Medical Sciences, [s. l.], v. 15, n. 4, p. 258–264, 2020. DOI: https://doi.org/10.1016/j.jtumed.2020.06.005

                AĞALAR, C.; ÖZTÜRK ENGIN, D. Protective measures for covid-19 for healthcare providers and laboratory personnel, 2020. DOI: https://doi.org/10.3906/sag-2004-132

                ALI, K.; RAJA, M. Coronavirus disease 2019 (COVID-19): challenges and management of aerosol-generating procedures in dentistry. Evidence-Based Dentistry, [s. l.], v. 21, n. 2, p. 44–45, 2020. DOI: https://doi.org/10.1038/s41432-020-0088-4

                AMATO, A.; CAGGIANO, M.; AMATO, M.; MOCCIA, G.; CAPUNZO, M.; DE CARO, F. Infection Control in Dental Practice During the COVID-19 Pandemic. International Journal of Environmental Research and Public Health, [s. l.], v. 17, n. 13, p. 4769, 2020. DOI: https://doi.org/10.3390/ijerph17134769

                BAGHIZADEH FINI, M. What dentists need to know about COVID-19, 2020. DOI: https://doi.org/10.1016/j.oraloncology.2020.104741

                BAXTER, D. Active and passive immunity, vaccine types, excipients and licensing. Occupational Medicine, [s. l.], v. 57, n. 8, p. 552–556, 2007. DOI: https://doi.org/10.1093/occmed/kqm110

                BHAGAVATHULA, A. S.; RAGHAVAN, V. R.; AHMADI, A.; SRIRAG, D.; CHATTU, V. K. Frontline Healthcare Workers’ Knowledge, Perception and Risk Prevention Practices Regarding COVID-19 in Afghanistan: A Cross-Sectional Study. Medical Sciences, [s. l.], v. 9, n. 1, p. 2, 2021. DOI: https://doi.org/10.3390/medsci9010002

                BRUM ELIANE, E. B. Pesquisa revela que Bolsonaro executou uma “estratégia institucional de propagação do coronavírus”. EL PAÍS, [s. l.], [s.d.].

                CADARI, M. B.; CACHONI, A. C.; TOLEDO NETO, J. L.; JASSI JOSÉ, F.; ZORZI COLÉTE, J.; FOGGIATO, A. A.; DA SILVA, D. F. Biosafety, life and COVID-19: Online questionnaire. International Journal of Advanced Engineering Research and Science, [s. l.], v. 8, n. 1, p. 059–068, 2021. DOI: https://doi.org/10.22161/ijaers.81.9

                CORMAN, V. M.; LANDT, O.; KAISER, M.; MOLENKAMP, R.; MEIJER, A.; CHU, D. K. W.; BLEICKER, T.; BRÜNINK, S.; SCHNEIDER, J.; SCHMIDT, M. L.; MULDERS, D. G. J. C.; HAAGMANS, B. L.; VAN DER VEER, B.; VAN DEN BRINK, S.; WIJSMAN, L.; GODERSKI, G.; ROMETTE, J. L.; ELLIS, J.; ZAMBON, M.; PEIRIS, M.; GOOSSENS, H.; REUSKEN, C.; KOOPMANS, M. P. G.; DROSTEN, C. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance, [s. l.], v. 25, n. 3, p. 1–8, 2020. DOI: https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045

                COULTHARD, P. Dentistry and coronavirus (COVID-19) - moral decision-making. British Dental Journal, [s. l.], 2020. DOI: https://doi.org/10.1038/s41415-020-1482-1

                DAI, X.; XIONG, Y.; LI, N.; JIAN, C. Vaccine Types. Vaccines - the History and Future, [s. l.], p. 1–9, 2019. DOI: https://doi.org/10.5772/intechopen.84626

                DALKY, H. F.; GHADER, N.; AL KUWARI, M.; ALNAJAR, M.; ISMAILE, S.; ALMALIK, M.; SHUDIFAT, R.; SANAD, S.; AL-NSAIR, N.; AL MATROOSHI, F. Assessment of the Awareness, Perception, Attitudes, and Preparedness of Health-care Professionals Potentially Exposed to COVID-19 in the United Arab Emirates. Journal of Multidisciplinary Healthcare, [s. l.], v. Volume 14, p. 91–102, 2021. DOI: https://doi.org/10.2147/JMDH.S278479

                EL-HAGE, W.; HINGRAY, C.; LEMOGNE, C.; YRONDI, A.; BRUNAULT, P.; BIENVENU, T.; ETAIN, B.; PAQUET, C.; GOHIER, B.; BENNABI, D.; BIRMES, P.; SAUVAGET, A.; FAKRA, E.; PRIETO, N.; BULTEAU, S.; VIDAILHET, P.; CAMUS, V.; LEBOYER, M.; KREBS, M.-O.; AOUIZERATE, B. Health professionals facing the coronavirus disease 2019 (COVID-19) pandemic: What are the mental health risks? L’Encéphale, [s. l.], v. 46, n. 3, p. S73–S80, 2020. DOI: https://doi.org/10.1016/j.encep.2020.04.008

                GE, Z.; YANG, L.; XIA, J.; FU, X.; ZHANG, Y. Possible aerosol transmission of COVID-19 and special precautions in dentistry. Journal of Zhejiang University-SCIENCE B, [s. l.], v. 21, n. 5, p. 361–368, 2020. DOI: https://doi.org/10.1631/jzus.B2010010

                GEORGER, F.; DOS SANTOS, E.; GAZAGNE, L.; BERDAGUÉ, P.; SAIB, A.; NAHON, S.; PIQUET, J.; AMARA, W. COV IMPACT : analyse des différents facteurs de stress du personnel hospitalier dans 2 centres hospitaliers en France lors de la pandémie COVID-19. Annales de Cardiologie et d’Angéiologie, [s. l.], v. 69, n. 5, p. 227–232, 2020. DOI: https://doi.org/10.1016/j.ancard.2020.09.005

                GURUPRASAD, L. Human SARS CoV-2 spike protein mutations. Proteins: Structure, Function, and Bioinformatics, [s. l.], p. prot.26042, 2021. DOI: https://doi.org/10.26434/chemrxiv.12827966

                HUI, D. S. Epidemic and Emerging Coronaviruses (Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome). Clinics in chest medicine, [s. l.], v. 38, n. 1, p. 71–86, 2017. DOI: https://doi.org/10.1016/j.ccm.2016.11.007

                IZZETTI, R.; NISI, M.; GABRIELE, M.; GRAZIANI, F. COVID-19 Transmission in Dental Practice: Brief Review of Preventive Measures in Italy. Journal of Dental Research, [s. l.], v. 99, n. 9, p. 1030–1038, 2020. DOI: https://doi.org/10.1177/0022034520920580

                JEAN, S. S.; HSUEH, P. R. Old and re-purposed drugs for the treatment of COVID-19. Expert Review of Anti-Infective Therapy, [s. l.], v. 18, n. 9, p. 843–847, 2020. DOI: https://doi.org/10.1080/14787210.2020.1771181

                JOAQUIM, B. F.; TOLEDO NETO, J. L.; COLÉTE, J. Z.; FOGGIATO, A. A.; SILVA, D. F. Dentistry biosecurity during the SARS-CoV-2 pandemic: what should we know? Joaquim,. [s. l.], p. 1–45, 2020.

                KAMPF, G.; TODT, D.; PFAENDER, S.; STEINMANN, E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. Journal of Hospital Infection, [s. l.], v. 104, n. 3, p. 246–251, 2020. DOI: https://doi.org/10.1016/j.jhin.2020.01.022

                KLIETZ, M.-L.; KAISER, H. W.; MACHENS, H.-G.; AITZETMÜLLER, M. M. Ac c ep te d Corresponding Author : an us cr ip t Ac c ep te d us cr t. [s. l.], p. 1–31, 2019.

                KRAMER, A.; SCHWEBKE, I.; KAMPF, G. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infectious Diseases, [s. l.], v. 6, n. 1, p. 130, 2006. DOI: https://doi.org/10.1186/1471-2334-6-130

                LAIGRET, J. La petite histoire de la découverte de la vaccination contre la fièvre jaune - Jean Laigret (1893-1966). Medecine tropicale : revue du Corps de sante colonial, [s. l.], v. 65, n. 3, p. 290–292, 2005.

                LOURENÇO, O. D.; JASSI, F. J.; COLÉTE, J. Z.; FOGGIATO, A. A.; TOLEDO NETO, J. L.; SILVA, D. F. STEM CELLS IN THE TREATMENT OF COVID-19 ACUTE RESPIRATORY SYNDROME: What do we know so far ? [s. l.], v. 10, p. 43079–43083, 2020.

                LU, Z. K.; YUAN, J.; LI, M.; SUTTON, S. S.; RAO, G. A.; JACOB, S.; BENNETT, C. L. Cardiac risks associated with antibiotics: Azithromycin and levofloxacin, 2015. DOI: https://doi.org/10.1517/14740338.2015.989210

                MADEWELL, Z. J.; YANG, Y.; JR, I. M. L.; HALLORAN, M. E.; DEAN, N. E. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1. medRxiv, [s. l.], p. 1–13, 2020.

                MAGAGNOLI, J.; NARENDRAN, S.; PEREIRA, F.; CUMMINGS, T.; HARDIN, J. W.; SUTTON, S. S.; AMBATI, J. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv, [s. l.], 2020. DOI: https://doi.org/10.1101/2020.04.16.20065920

                MAHÉVAS, M.; TRAN, V. T.; ROUMIER, M.; CHABROL, A.; PAULE, R.; GUILLAUD, C.; GALLIEN, S.; LEPEULE, R.; SZWEBEL, T. A.; LESCURE, X.; SCHLEMMER, F.; MATIGNON, M.; KHELLAF, M.; CRICKX, E.; TERRIER, B.; MORBIEU, C.; LEGENDRE, P.; DANG, J.; SCHOINDRE, Y.; PAWLOTSKI, J. M.; MICHEL, M.; PERRODEAU, E.; CARLIER, N.; ROCHE, N.; DE LASTOURS, V.; MOUTHON, L.; AUDUREAU, E.; RAVAUD, P.; GODEAU, B.; COSTEDOAT-CHALUMEAU, N. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: Results of a study using routinely collected data to emulate a target trial. medRxiv, [s. l.], p. 1–20, 2020. DOI: https://doi.org/10.1101/2020.04.10.20060699

                MARTIN, C. Tuberculosis vaccines: Past, present and future. Current Opinion in Pulmonary Medicine, [s. l.], v. 12, n. 3, p. 186–191, 2006. DOI: https://doi.org/10.1097/01.mcp.0000219267.27439.1b

                MENG, L.; HUA, F.; BIAN, Z. Coronavirus Disease 2019 (COVID-19): Emerging and Future Challenges for Dental and Oral Medicine. Journal of Dental Research, [s. l.], v. 99, n. 5, p. 481–487, 2020. DOI: https://doi.org/10.1177/0022034520914246

                MODELLI, L. 4 vacinas contra a Covid apresentam taxas satisfatórias de eficácia e de segurança; veja comparativo. [s.d.].

                MODI, P. D.; NAIR, G.; UPPE, A.; MODI, J.; TUPPEKAR, B.; GHARPURE, A. S.; LANGADE, D. COVID-19 Awareness Among Healthcare Students and Professionals in Mumbai Metropolitan Region: A Questionnaire-Based Survey. Cureus, [s. l.], 2020. DOI: https://doi.org/10.7759/cureus.7514

                NAGY, Á.; PONGOR, S.; GYŐRFFY, B. Different mutations in SARS-CoV-2 associate with severe and mild outcome. International Journal of Antimicrobial Agents, [s. l.], v. 57, n. 2, p. 106272, 2021. DOI: https://doi.org/10.1016/j.ijantimicag.2020.106272

                NUNES, K. Ineficaz contra a Covid-19, ivermectina tem aumento de 615% nas vendas em Pernambuco. Brasil de fato - pernanbuco, [s. l.], [s.d.].

                ORTEGA, R.; GONZALEZ, M.; NOZARI, A.; CANELLI, R. Personal Protective Equipment and Covid-19. New England Journal of Medicine, [s. l.], 2020. DOI: https://doi.org/10.1056/NEJMvcm2014809

                OTTER, J. A.; YEZLI, S.; SALKELD, J. A. G.; FRENCH, G. L. Evidence that contaminated surfaces contribute to the transmission of hospital pathogens and an overview of strategies to address contaminated surfaces in hospital settings. American Journal of Infection Control, [s. l.], v. 41, n. 5, p. S6–S11, 2013. DOI: https://doi.org/10.1016/j.ajic.2012.12.004

                PASCARELLA, G.; STRUMIA, A.; PILIEGO, C.; BRUNO, F.; DEL BUONO, R.; COSTA, F.; SCARLATA, S.; AGRÒ, F. E. COVID-19 diagnosis and management: a comprehensive review, 2020. DOI: https://doi.org/10.1111/joim.13091

                PASSARINHO, N. A potencial vantagem da CoronaVac contra variantes do coronavírus. [s.d.].

                PEELING, R. W.; WEDDERBURN, C. J.; GARCIA, P. J.; BOERAS, D.; FONGWEN, N.; NKENGASONG, J.; SALL, A.; TANURI, A.; HEYMANN, D. L. Serology testing in the COVID-19 pandemic response. The Lancet Infectious Diseases, [s. l.], v. 20, n. 9, p. e245–e249, 2020. DOI: https://doi.org/10.1016/S1473-3099(20)30517-X

                PLOTKIN, S. History of vaccination, 2014. DOI: https://doi.org/10.1016/B978-1-4557-0090-5.00017-3

                PLOTKIN, S. A. Vaccines: Past, present and future. Nature Medicine, [s. l.], v. 11, n. 4S, p. S5, 2005. DOI: https://doi.org/10.1038/nm1209

                PLOTKIN, S. A.; GILBERT, P. B. Nomenclature for immune correlates of protection after vaccination. Clinical Infectious Diseases, [s. l.], 2012. DOI: https://doi.org/10.1093/cid/cis238

                POR G1. Vacinação contra a Covid-19 no Brasil: veja perguntas e respostas. [s. l.], [s.d.].

                ROBSON, B. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles’ heel conserved region to minimize probability of escape mutations and drug resistance. Computers in Biology and Medicine, [s. l.], v. 121, p. 103749, 2020. DOI: https://doi.org/10.1016/j.compbiomed.2020.103749

                ROSENBERG, E. S.; DUFORT, E. M.; UDO, T.; WILBERSCHIED, L. A.; KUMAR, J.; TESORIERO, J.; WEINBERG, P.; KIRKWOOD, J.; MUSE, A.; DEHOVITZ, J.; BLOG, D. S.; HUTTON, B.; HOLTGRAVE, D. R.; ZUCKER, H. A. Association of Treatment with Hydroxychloroquine or Azithromycin with In-Hospital Mortality in Patients with COVID-19 in New York State. JAMA - Journal of the American Medical Association, [s. l.], 2020. DOI: https://doi.org/10.1001/jama.2020.8630

                ROTHAN, H. A.; BYRAREDDY, S. N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak, 2020. DOI: https://doi.org/10.1016/j.jaut.2020.102433

                SAKAMOTO, L. S. Ivermectina, como o governo Bolsonaro, não tem eficácia contra a covid-19. [s.d.].

                SHEREEN, M. A.; KHAN, S.; KAZMI, A.; BASHIR, N.; SIDDIQUE, R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. Journal of Advanced Research, [s. l.], v. 24, p. 91–98, 2020. DOI: https://doi.org/10.1016/j.jare.2020.03.005

                SILVA, L. B. Covid-19: Cepa de Manaus pode comprometer desenvolvimento de anticorpos, diz OMS. [s.d.]. Disponível em: <https://www.cnnbrasil.com.br/saude/2021/02/10/covid-19-cepa-de-manaus-pode-comprometer-desenvolvimento-de-anticorpos-diz-oms>.

                STRUNK, J. L.; TEMESGEN, H.; ANDERSEN, H.; PACKALEN, P. In Pr es s In es. [s. l.], v. 80, n. 2, p. 1–8, 2014. DOI: https://doi.org/10.14358/PERS.80.2.143-150

                THANH LE, T.; ANDREADAKIS, Z.; KUMAR, A.; GÓMEZ ROMÁN, R.; TOLLEFSEN, S.; SAVILLE, M.; MAYHEW, S. The COVID-19 vaccine development landscape. Nature reviews. Drug discovery, [s. l.], v. 19, n. 5, p. 305–306, 2020. Disponível em: <http://dx.doi.org/10.1038/d41573-020-00073-5> DOI: https://doi.org/10.1038/d41573-020-00073-5

                WANG, P. W.; LU, W. H.; KO, N. Y.; CHEN, Y. L.; LI, D. J.; CHANG, Y. P.; YEN, C. F. COVID-19-Related Information Sources and the Relationship with Confidence in People Coping with COVID-19: Facebook Survey Study in Taiwan, 2020. DOI: https://doi.org/10.2196/preprints.20021

                WHO. Rational use of personal protective equipment for coronavirus disease 2019 ( COVID-19 ). World Health Organization, [s. l.], v. 27, n. February, p. 1–7, 2020.

                WORLD HEALTH ORGANIZATION. Laboratory biosafety guidance related to coronavirus disease (COVID-19). Interim guidance, [s. l.], n. 19 March, p. 1–5, 2020. a.

                WORLD HEALTH ORGANIZATION. Laboratory biosafety guidance related to the novel coronavirus ( 2019-nCoV ). World Health Organisation, [s. l.], n. February, p. 1–12, 2020. b.

                WORLD HEALTH ORGANIZATION (WHO). Rational use of personal protective equipment for coronavirus disease 2019 ( COVID-19 ). World Health Organization, [s. l.], 2020.

                Downloads

                Published

                2021-04-01

                How to Cite

                Cachoni, A. C., Cadari, M. B., Foggiato, A. A., Coléte, J. Z., Neto, J. L. T., Jassi, F. J., & Silva, D. F. da. (2021). Biosafety and action in front of COVID-19: What do we know? International Journal for Innovation Education and Research, 9(4), 129-141. https://doi.org/10.31686/ijier.vol9.iss4.3031